(R)-3-(3-Methylbutanoyl)-4-Benzyloxazolidin-2-One

We are (R)-3-(3-Methylbutanoyl)-4-Benzyloxazolidin-2-One CAS:145589-03-3 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name: (R)-3-(3-Methylbutanoyl)-4-Benzyloxazolidin-2-One
CAS.NO:145589-03-3
Synonyms:
(R)-4-Benzyl-3-(3-methylbutanoyl)oxazolidin-2-one
(4R)-4-benzyl-3-(3-methylbutanoyl)-1,3-oxazolidin-2-one

Molecular Formula:C15H19NO3
Molecular Weight:261.31600

Physical and Chemical Properties:
Density: 1.152
Boiling point: 412.9ºC at 760mmHg
Melting point: /
Flash point: 203.5ºC
Refractive index: 1.541

Specification:
Appearance:white  powder
Purity:≥98%

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:Intermediates of Aliskiren CAS:173334-57-1
Intermediates of Aliskiren hemifumarate CAS:173334-58-2

Related News: Slower growth in pesticide intermediates weighed on industrial business. In the first three quarters, the company’s operating income was 2.977 billion yuan, a year-on-year increase of 2.57%.2-(3,4-Dihydro-4-oxo-1,2,3-benzotriazin-3-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate CAS:164861-52-3 “We believe the iLet Bionics Pancreas System represents a true breakthrough therapy for the management of glycemia, particularly in type 1 diabetes,” said Ed Damiano, President and CEO of Beta Bionics. “We are partuclarly excited by the possibility that the iLet may be able to provide safer and more effective therapy in far more people than current therapies due to its simplicity of use.”3-hidroxi-4-metoxibenzonitrilo CAS:52805-46-6 Multinational drugmakers usually cut the price of drugs when they go off-patent and face competition from generic versions, but such price drops were slow to happen in China, partially because many local drugmakers were unable to develop high-quality generic drugs to compete with off-patent branded drugs.95-53-4 Resonant exploits its proprietary IMPaCT tumor microenvironment models and data platform to discover novel, unappreciated targets and functionally active anti-tumor antibodies for difficult to treat tumors.Steven M. Fruchtman, M.D., President and Chief Executive Officer of Onconova, added “The rigosertib Pre-approval Access Program is a key strategic initiative for Onconova.